🇺🇸 FDA
Patent

US 9562230

Transferrin/transferrin receptor-mediated siRNA delivery

granted A61KA61K31/7088A61K31/713

Quick answer

US patent 9562230 (Transferrin/transferrin receptor-mediated siRNA delivery) held by Arrowhead Pharmaceuticals, Inc. expires Mon Feb 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arrowhead Pharmaceuticals, Inc.
Grant date
Tue Feb 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K31/7088, A61K31/713, A61K47/64, A61K47/644